Who is sponsoring NCT05165615?

NCT05165615 is sponsored by Charles University, Czech Republic.

What drugs are being tested in NCT05165615?

Interventions in NCT05165615: Insulin Pump t:slim X2 with Control-IQ technology.

What condition does NCT05165615 study?

NCT05165615 studies Diabetes Mellitus, Type 1.

Is NCT05165615 still recruiting?

NCT05165615 is currently status unknown. Last updated 21 December 2021.

Last reviewed 2021-12-21 · How we verify

NCT05165615: CODIAC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Android Artificial Pancreas System (Android APS) Versus Control-IQ

Status unknown NA Last updated 21 December 2021

What this trial tests

NA trial testing Insulin Pump t:slim X2 with Control-IQ technology in Diabetes Mellitus, Type 1 in 20 participants. Status unknown.

Timeline

1 December 2020

Primary endpoint
30 June 2022

31 December 2022

Quick facts

Lead sponsor	Charles University, Czech Republic
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	20
Start date	1 December 2020
Primary completion	30 June 2022
Estimated completion	31 December 2022
Sites	1 location across Czechia

Drugs / interventions tested

Insulin Pump t:slim X2 with Control-IQ technology

Conditions studied

Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →

Sponsor

Charles University, Czech Republic

Who can join

18 and older, any sex, with Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the investigator's study is to compare two different closed loop hybrid systems - certified Control-IQ and noncertified AndroidAPS in adult patients with Type 1 Diabetes (T1D), who had been using AndroidAPS previously from their own decision, during 12 weeks of follow-up.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

58<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes : Stockholm, Sweden, 19 - 23 September 2022.
· 2022 · cited 6× · PMID 35920845 · DOI 10.1007/s00125-022-05755-w

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 1

Currently open trials in the same condition.

NCT07325461 — Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes · NA · recruiting
NCT07305805 — A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes · Phase 1 · recruiting
NCT06282055 — Trajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes · recruiting
NCT06325202 — Closed Loop and Education for Hypoglycemia Awareness Restoration · NA · recruiting
NCT07160816 — A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar · recruiting

Other Charles University, Czech Republic trials

Trials by the same sponsor.

NCT07475481 — Exercise-Based Strategies for Chronic Back Pain · NA · not yet recruiting
NCT07468318 — Multimodal Therapy for Somatosensory Tinnitus · NA · not yet recruiting
NCT07525154 — Development of a Certified Testing Procedure for Hip and Groin Injuries in Athletes · NA · not yet recruiting
NCT07512570 — Feasibility and Preliminary Effects of a Structured Resistance Training Program in Children Aged 10-14 Years · NA · not yet recruiting
NCT07424326 — Extended Ablation Versus Pulmonary Vein Isolation to Treat Persistent Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05165615 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Charles University, Czech Republic
Last refreshed: 21 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05165615.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing